Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck.

Next Previous
Trial Profile

A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use

Most Recent Events

  • 07 Jun 2016 Results of an exploratory analysis assessing racial disparity in oncologic and patient-reported quality of life presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
  • 17 Jul 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2012 as reported by ClinicalTrials.gov.
  • 17 Jul 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top